Aberdeen Wealth Management LLC Invests $843,000 in Abbott Laboratories $ABT

Key Points

• Aberdeen Wealth Management acquired 9,291 Abbott shares worth approximately $843,000 in the second quarter, while institutional investors collectively own 75.18% of the company.
• Wall Street remains bullish, with a consensus “Moderate Buy” rating and an average price target of $119.50. Recent quarterly results beat estimates, with revenue up 13% year over year and full-year 2026 guidance reaffirmed.
• Abbott launched a ready-to-feed whole-milk Similac formula that could support Nutrition-segment growth, although competitive advertising scrutiny and uncertain consumer demand remain risks.

Aberdeen Wealth Management LLC acquired a new position in Abbott Laboratories (NYSE:ABT - Free Report) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 9,291 shares of the healthcare product maker's stock, valued at approximately $843,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Visionary Wealth Advisors purchased a new position in shares of Abbott Laboratories during the 2nd quarter worth $348,000. Ames National Corp purchased a new stake in Abbott Laboratories in the 2nd quarter valued at about $211,000. Asset One Wealth Management LLC purchased a new stake in Abbott Laboratories in the 2nd quarter valued at about $328,000. Safeguard Investment Advisory Group LLC acquired a new position in Abbott Laboratories in the second quarter valued at about $273,000. Finally, Ally Financial Inc. purchased a new position in Abbott Laboratories during the second quarter worth about $7,350,000. Hedge funds and other institutional investors own 75.18% of the company's stock.

Wall Street Analysts Forecast Growth

ABT has been the subject of several research reports. BTIG Research lifted their target price on shares of Abbott Laboratories from $131.00 to $134.00 and gave the company a "buy" rating in a report on Friday, July 17th. Piper Sandler restated an "overweight" rating and set a $118.00 price target (up from $115.00) on shares of Abbott Laboratories in a research report on Friday, July 17th. Wells Fargo & Company lifted their price objective on Abbott Laboratories from $109.00 to $112.00 and gave the company an "overweight" rating in a research note on Friday, July 17th. Wolfe Research upgraded Abbott Laboratories from a "peer perform" rating to an "outperform" rating and set a $130.00 price objective on the stock in a report on Thursday, August 13th. Finally, JPMorgan Chase & Co. raised their target price on Abbott Laboratories from $110.00 to $120.00 and gave the company an "overweight" rating in a report on Friday, July 17th. Three analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and four have issued a Hold rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $119.50.

Abbott Laboratories News Summary

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: New infant formula expands Abbott’s nutrition portfolio. Abbott launched Similac 360 Total Care Made With Whole Milk, described as the first commercially sterile, ready-to-feed liquid whole-milk infant formula available in the U.S. The product targets growing parental interest in whole-milk formulas while offering convenience at a price similar to Similac’s powdered formula. Wider distribution and consumer adoption could provide incremental growth for Abbott’s Nutrition segment. Abbott launches whole-milk liquid infant formula
• Positive Sentiment: Analysts remain optimistic despite relative underperformance. Coverage notes that ABT has lagged the broader healthcare sector over the past year, but Wall Street analysts continue to express confidence in the company’s outlook. Recent earnings also showed revenue growth, an earnings-per-share beat and reaffirmed 2026 guidance, supporting the bullish view. Abbott stock and healthcare-sector performance
• Neutral Sentiment: Abbott is positioning the launch around changing consumer and policy preferences. The whole-milk formula introduction aligns with interest in “Make America Healthy Again” themes, but the financial impact will depend on demand, pricing and market share gains. Abbott and the Make America Healthy Again movement
• Negative Sentiment: Formula-related advertising scrutiny remains a risk. In a challenge brought by Abbott, the National Advertising Division supported certain Kendamil whole-milk claims but recommended that other nutritional, ingredient and heritage claims be modified or discontinued. The decision is not a direct finding against Abbott, but it highlights competitive scrutiny in the infant-formula market. NAD decision on Kendamil infant formula claims

Abbott Laboratories Stock Performance

Shares of Abbott Laboratories stock opened at $108.86 on Wednesday. Abbott Laboratories has a one year low of $81.97 and a one year high of $137.49. The company has a market cap of $188.37 billion, a PE ratio of 35.23, a P/E/G ratio of 2.05 and a beta of 0.59. The company has a debt-to-equity ratio of 0.57, a quick ratio of 0.97 and a current ratio of 1.38. The business has a 50-day simple moving average of $103.43 and a 200-day simple moving average of $100.09.

Abbott Laboratories (NYSE:ABT - Get Free Report) last posted its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 EPS for the quarter, topping the consensus estimate of $1.28 by $0.03. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The company had revenue of $12.59 billion during the quarter, compared to analysts' expectations of $12.52 billion. During the same quarter in the previous year, the business posted $1.26 EPS. The firm's revenue was up 13.0% on a year-over-year basis. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. On average, equities research analysts forecast that Abbott Laboratories will post 5.52 EPS for the current fiscal year.

Abbott Laboratories Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th were issued a dividend of $0.63 per share. The ex-dividend date of this dividend was Wednesday, July 15th. This represents a $2.52 dividend on an annualized basis and a yield of 2.3%. Abbott Laboratories's dividend payout ratio (DPR) is presently 81.55%.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source